Buy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA Treatment

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Larimar Therapeutics (LRMR – Research Report). The associated price target remains the same with $27.00.

Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Larimar Therapeutics’ advancements in its clinical programs and promising therapeutic potential. Specifically, the release of positive top-line Phase II data for Larimar’s nomlabofusp in treating Friedreich’s ataxia (FA) is a major contributor. The treatment demonstrated significant improvements in frataxin protein levels in patients, which correlates with the potential to slow disease progression and improve quality of life. These results suggest that nomlabofusp could be effective in reaching key tissues affected by FA, supporting the potential for long-term benefits to patients.

Furthermore, the initiation of an open-label extension (OLE) study provides an opportunity to evaluate the long-term safety and efficacy of nomlabofusp. The OLE study’s alignment with the Friedreich’s Ataxia Research Alliance’s (FARA) clinical research network sites in the US is also seen as strategic, facilitating the potential for expanded patient access and streamlined data collection. The data collected in the OLE study is expected to be instrumental for a potential Biologics License Application (BLA) submission, highlighting Larimar’s commitment to advancing its therapeutic options for FA patients. These factors collectively underscore the Buy rating assigned by Cory Jubinville, PhD.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LRMR in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Larimar Therapeutics (LRMR) Company Description:

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.